MCM
CHRS icon

Mazama Capital Management’s Coherus Oncology CHRS Stock Holding History

Mazama Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,366
Closed -$31K – 30
2015
Q4 		$31K Buy
1,366
+63
+5% +$1.62K 0.01% 235
2015
Q3 		$26K Sell
1,303
-241
-16% -$7.33K 0.01% 232
2015
Q2 		$45K Sell
1,544
-32,323
-95% -$817K 0.01% 220
2015
Q1 		$1.04M Sell
33,867
-29,768
-47% -$769K 0.21% 130
2014
Q4 		$1.04M Buy
+63,635
New +$898K 0.24% 125

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Mazama Capital Management's CHRS Position: Q1 2016 in Review

Mazama Capital Management sold out of Coherus Oncology (CHRS) in Q1 2016, closing a stake of 1,366 shares — an estimated $31K sold.

Mazama Capital Management first reported a position in CHRS in Q4 2014 and held it in 5 quarters. The position peaked at $1.04M in Q4 2014. 75 funds tracked by Wall St. Rank hold CHRS as of Q1 2016.

  • Mazama Capital Management reported no remaining Coherus Oncology position as of Q1 2016 after selling out during the quarter.
  • Mazama Capital Management sold 1,366 Coherus Oncology shares in Q1 2016, an estimated $31K.
  • Mazama Capital Management first reported a position in Coherus Oncology in Q4 2014 and held it in 5 quarters.
  • Mazama Capital Management's Coherus Oncology position peaked at $1.04M in Q4 2014.
  • 75 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.